Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome

NCT03094832 is registered in ClinicalTrials.gov with ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) as lead sponsor.

NCT NCT03094832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03094832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase
Phase 1/2
Overall status
Terminated
Start date
May 16, 2017
Completion date
April 11, 2022
Enrollment
50 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pik3ca-related overgrowth spectrum (pros)/proteus syndrome